Spots Global Cancer Trial Database for Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
Official Title: An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination With mFOLFOX6 (Oxaliplatin, 5-Fluorouracil, and Folinic Acid) Versus Bevacizumab in Combination With mFOLFOX6 as Second-line Treatment of Subjects With Advanced Colorectal Cancer
Study ID: NCT00707889
Study Description
Brief Summary: To determine the effect of ABT-869 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 on disease progression in advanced colorectal cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Site Reference ID/Investigator# 11341, Chapel Hill, North Carolina, United States
Site Reference ID/Investigator# 20801, Philadelphia, Pennsylvania, United States
Site Reference ID/Investigator# 8360, Nashville, Tennessee, United States
Site Reference ID/Investigator# 18581, Bedford Park, , Australia
Site Reference ID/Investigator# 23443, Herston, , Australia
Site Reference ID/Investigator# 18023, Bonheiden, , Belgium
Site Reference ID/Investigator# 23646, Brussels, , Belgium
Site Reference ID/Investigator# 18026, Leuven, , Belgium
Site Reference ID/Investigator# 18022, Roeselare, , Belgium
Site Reference ID/Investigator# 26662, Jau, , Brazil
Site Reference ID/Investigator# 24245, Porto Alegre, , Brazil
Site Reference ID/Investigator# 23265, Barrie, , Canada
Site Reference ID/Investigator# 21083, Edmonton, , Canada
Site Reference ID/Investigator# 22465, Ottawa, , Canada
Site Reference ID/Investigator# 22141, Nachod, , Czech Republic
Site Reference ID/Investigator# 22289, Heraklion, , Greece
Site Reference ID/Investigator# 22286, Thessaloniki, , Greece
Site Reference ID/Investigator# 22287, Thessaloniki, , Greece
Site Reference ID/Investigator# 18281, Seoul, , Korea, Republic of
Site Reference ID/Investigator# 18283, Seoul, , Korea, Republic of
Site Reference ID/Investigator# 18282, Seoul, , Korea, Republic of
Site Reference ID/Investigator# 20281, Wellington South, , New Zealand
Site Reference ID/Investigator# 20141, Olsztyn, , Poland
Site Reference ID/Investigator# 17946, Warsaw, , Poland
Site Reference ID/Investigator# 38284, Warsaw, , Poland
Site Reference ID/Investigator# 23908, Aveiro, , Portugal
Site Reference ID/Investigator# 22324, Coimbra, , Portugal
Site Reference ID/Investigator# 23724, Faro, , Portugal
Site Reference ID/Investigator# 23964, Lisbon, , Portugal
Site Reference ID/Investigator# 23303, Baia Mare, , Romania
Site Reference ID/Investigator# 23302, Brasov, , Romania
Site Reference ID/Investigator# 17962, Bucharest, , Romania
Site Reference ID/Investigator# 17964, Bucharest, , Romania
Site Reference ID/Investigator# 23304, Bucharest, , Romania
Site Reference ID/Investigator# 17961, Cluj Napoca, , Romania
Site Reference ID/Investigator# 23305, Craiova, , Romania
Site Reference ID/Investigator# 24422, Moscow, , Russian Federation
Site Reference ID/Investigator# 25063, Moscow, , Russian Federation
Site Reference ID/Investigator# 25065, Moscow, , Russian Federation
Site Reference ID/Investigator# 24423, Moscow, , Russian Federation
Site Reference ID/Investigator# 22809, A Coruna, , Spain
Site Reference ID/Investigator# 22807, Barcelona, , Spain
Site Reference ID/Investigator# 22804, Madrid, , Spain
Site Reference ID/Investigator# 22801, Madrid, , Spain
Site Reference ID/Investigator# 22803, Pamplona Navarra, , Spain
Site Reference ID/Investigator# 22800, Santander, , Spain
Contact Details
Name: Mark D. McKee, MD
Affiliation: AbbVie
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
